Related resources and publications
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.
The humanized CTLA‑4 mouse model (hCTLA-4) is developed by Knockin at the mouse CTLA‑4 locus, and enables the expression of: a) the full-length chimeric CTLA-4 isoform; and b) the soluble isoform.
The design also gives access to CTLA-4 conditional Knockout mice for a tissue-specific assessment of compounds’ specificity and toxicity.
hCTLA-4 and mCTLA-4 expression on αCD3-activated splenocytes on A) Tregs (viable, CD3+CD4+CD25+Foxp3+), B) conventional CD4+ (viable, CD3+CD4+Foxp3-) at day 3, and C) CD8+ (viable, CD3+CD8+) T cells at indicated time points.
Wild-type and hCTLA-4 mice were implanted s.c. with MC38 tumor on day 0 with n=10 mice per group. Survival of mice treated with αhCTLA-4 (ipilimumab), αmCTLA-4 (9H10) or isotype i.p. bi-weekly for 4 weeks.
(Mantel-Cox test: ****p<0.0001)
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help